An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

Clinical trial NCT00235300 · COMPLETED

Trial details

NCT number: NCT00235300
Sponsor: Genzyme, a Sanofi Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Cadaveric Donor Renal Transplantation Acute Renal Allograft Rejection Induction Therapy

Start date: 2000-05-01
Primary completion: 2003-04-01
Enrollment: 240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.